Barclays on Xeris Pharmaceuticals (XERS): 'LOE concerns overblown'

Barclays analyst Jenna Davidner reiterated an Overweight rating and $9.00 price target on Xeris Pharmaceuticals (NASDAQ: XERS)

The analyst commented, "Current Mkt Cap <$1B Feels Punitive Given $4B Peak Sales: LOE Concerns Feel Overblown With a breakout year in 2025 (shares +130%), XERS stock has been volatile in 2026 due primarily to 1) Recorlev LOE concerns and 2) macro volatility. While we have less visibility into the macro, we think the LOE concerns are overblown and came away from our Miami conf with increased conviction."

For an analyst ratings summary and ratings history on Xeris Pharmaceuticals click here. For more ratings news on Xeris Pharmaceuticals click here.

Shares of Xeris Pharmaceuticals closed at $5.43 yesterday.

You May Also Be Interested In

• Barclays Downgrades SES SA (SESG:FP) (SGBAF) to Underweight
• BMO Capital Starts Apotex Health Corp (APTX:CN) at Outperform
• Jefferies Upgrades Yihai International Holding Ltd. (1579:HK) (YNNHF) to Buy